Title : Guillain- barre syndrome following sinovac (Coronavac) Covid-19 vaccination: A case report in Cagayan Valley
Abstract:
Introduction:
Guillain-Barré syndrome (GBS) following COVID-19 vaccination has been reported in the scientific literature. Although causality cannot be ascertained, this case of GBS is reported, to highlight the diagnosis, management and incidence of this important adverse event following immunization.
Case:
This is a case of a 57-year-old female with ascending sensorimotor neuropathy of the lower extremities following Sinovac (Coronavac) vaccination in Cagayan Valley. She had no history of either diarrhea or respiratory tract infections, but had her first dose of Sinovac two days prior to the onset of symptoms. Clinical examination, cerebrospinal fluid analyses and electrodiagnostic testing were consistent with GBS. The patient was admitted with a GBS Disability Score of 4.
Intravenous immunoglobulins (0.4g/kg per day for 5 days) were started upon diagnosis and resolution of sensory deficit after the infusion was observed. Dysautonomia (tachycardia and hypertension), hyperglycemia and glucosuria were also noted during the hospitalization. The patient was discharged after 3 weeks with a GBS Disability Score of 3. Physical rehabilitation was continued in the out- patient care. The GBS Disability score improved to 2 on the 8th week of illness and she was able to walk and run without difficulty (GBS Disability Score 0) on Week 38.
Conclusion:
Though causality between COVID-19 vaccination and GBS incidence has not been fully established, it is prudent to be vigilant to present and report any adverse event or relevant case that may be related to the vaccine.
Audience Take Away:
- Present a case, which is temporally related to a vaccine (Sinovac)
- Diagnosis of GBS in a limited resource setting.
- Management of GBS and physical rehabilitation
